Member Info for TRENCH123

Porky/Viera why are you so obsessed with Valirx. There is obviously more to it than meets the eye. I can only assume that you have a vested interest in the placings, otherwise why waste your time and energy. Clearly you are not doing it to help anyone other than yourself. Honest replies only please

Yes , an extremely well-written and balanced article. Appears to omit any reference to the advanced work on the personalised dosing tool which could be the most transformative for the company

Be interesting if the likes of Doc Holliday started to take an interest here on such a low mcap.

Looks like a very successful fundraise

Great to meet the @Physiomics team in Oxford over the last 2 days.

We discussed A.I opportunities consistent with #PYC I.T infrastructure, future proofing the business.

Productive 2 days 💪

Fair point

I am not invested here (and am not intending to) but was struck by the extremely positive comments of by both the Chairman and CEO respectively :-

'ValiRx is building an asset rich business which, we believe is massively undervalued. The current raise is a testament to this."

"We believe the current valuation does not fully reflect the breadth of assets, intellectual property and commercial optionality within the Group, and this fundraising is designed to help unlock several potential near-term catalysts."

Will be money well spent if he is able to accelerate commercialisation of PYC dosing tool. I am looking forward to news of progress on the G-CSF trial which could be a real game-changer here

The eternal pessimist is alive and kicking

I agree Laura. Pete's knowledge of PYC and industry contacts would be invaluable

Investors waiting for announcements from new BOD, but this is not something which can be rushed. Patience required

£13k buy at the end of the day

Must be staying on during transition. Hope so, some continuity very useful

Congratulations to Mike and team. Genuine shareholders are behind your efforts to grow the business

Hits, of relevance now is the present and future position. PYC have demonstrated a turn around in their fortunes and with the commercialisation of their personalised dosing tool in prospect I feel that your assessment of the BOD performance is too negative. Given time I believe the company would be able to capitalise on its position and the share price recover significantly, but your impatience will very likely not allow this to happen now. Whilst welcoming your intervention, I think you have taken a far too aggressive approach which I do not particularly care for (obviously many others do) and which cannot give the best outcome. The various write-ups which you have influenced have not been from someone who has the best interests of PYC the company at their heart. They have undermined the reputation of the company and this is in the interests of no one. I think you need to tone down the rhetoric.

These are my honest opinions, but I will not be entering into further dialogue on the comments

Nothing new here. Same old, same old - as we have had for too long now. Let's get the vote sorted and support whoever wins

The flurry of activity by the existing BOD suggests a confidence that they can deliver for shareholders, but will they be given the chance ?

I suspect that there is much more to this than meets the eye. It could be that there is significant business news imminent and Jim is concerned that this will not materialise without senior director continuity

I will give you my two penny’orth for what its worth (and probably not a lot !!)

I think the criticism of JM has been OTT in some instances. Key initiatives which are now creating more interest in PYC - the Biostatistics offering and personalised dosing tool development - are his. Obviously PS has shown great abilities in following these through and advancing them

Having followed PYC for a long time I have found that JM has always been consistent in his explanation of progress within the company. The fact that progress has been slower than some hoped has been to some extent outside the control of the company and has affected companies industry wide, but the opportunities to capitalise on progress made in key areas are real and closer than ever and the present trajectory is a good one

I believe the intentions of the existing BOD and proposed BOD are good and would be happy to see some changes. I just don’t see the radical changes on offer being the best alternative at this time. I think both sides need to step back and act professionally in the best interests of all shareholders. I still think PYC will be successful, but the current wrangling will not give the best possible outcome and for that reason I am stepping aside from voting.

Welcome news